The DOI matches its Crossref record; the references it cites are not checked yet.
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
Abstract
Background: The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular outcomes have not been well established. We pooled evidence from all available clinical trials to assess the cardiovascular effects of this drug. Design: A systematic review and meta-analysis of randomised controlled trials. Methods: We queried electronic databases (MEDLINE, Scopus, CENTRAL and clinicaltrials.gov) from their inception to July 2017 for published and unpublished placebo controlled trials of SGLT2 inhibitors. Only studies with a follow-up period of at least 24 weeks and reporting at least one cardiovascular outcome were included. Results from trials were presented as odds ratios (ORs) with 95% confidence intervals (CIs) and were pooled using a random-effects model. Results: Thirty-five eligible studies (canagliflozin, nine; empagliflozin, eight; dapagliflozin, 18), consisting of 34,987 patients with type 2 diabetes mellitus were included. Pooled results show that SGLT2 inhibitors, when compared to placebo, significantly reduce all-cause mortality (OR 0.79, 95% CI 0.70–0.89; P < 0.001), major adverse cardiac events (OR 0.8, 95% CI 0.76–0.92; P < 0.001), non-fatal myocardial infarction (OR 0.85, 95% CI 0.73–0.98; P = 0.03) and heart failure/hospitalisation for heart failure (OR 0.67, 95% CI 0.59–0.76; P < 0.001) in patients with type 2 diabetes mellitus. No significant difference was noted in the occurrence of stroke (OR 1.02, 95% CI 0.85–1.21; P = 0.87), atrial fibrillation (OR 0.61, 95% CI 0.31–1.19; P = 0.15) or unstable angina (OR 0.95, 95% CI 0.73–1.25; P = 0.73). In addition, there was no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied ( I 2 = 0). Conclusions: SGLT2 inhibitors significantly reduce the incidence of mortality, major adverse cardiac events, non-fatal myocardial infarction and heart failure in patients with type 2 diabetes mellitus. Subtypes of SGLT2 inhibitors appear to have similar cardiovascular effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitors do not reduce the risk of ischemic stroke incidence, they affect the most important cerebrovascular risk factors, including hyperglycemia, hypertension, obesity, dyslipidemia, and atherosclerosis [112].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [112]
In the citing paper
“Although SGLT2 inhibitors do not reduce the risk of ischemic stroke incidence, they affect the most important cerebrovascular risk factors, including hyperglycemia, hypertension, obesity, dyslipidemia, and atherosclerosis [112].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [112]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 27 · Cited by 160
Metadata
- Authors
- Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y.
- Affiliations
- Dow University of Health Sciences (PK)
- Cook County Health and Hospitals System (US)
- University of Louisville (US)
- Division of Cardiology, Cook County Health and Hospitals System, USA
- Corresponding author
- Siddiqi, Tariq Jamal
- ORCID
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-26
- Volume
- 25
- Issue
- 5
- Pages
- 495-502
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2793012836
- Cited by
- 160
- References
- 27
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 21 · 2023: 21 · 2022: 27 · 2021: 18 · 2020: 29 · 2019: 15 · 2018: 9
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- SGLT2 inhibitors, cardiovascular outcomes, type 2 diabetes, canagliflozin, empagliflozin, dapagliflozin, all-cause mortality, major adverse cardiac events, myocardial infarction, heart failure hospitalization, stroke, atrial fibrillation, unstable angina, drug safety, drug efficacy
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Humans, Prognosis, Global Health, Incidence, Survival Rate, Randomized Controlled Trials as Topic, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1177/2047487318755531
- The paper
- Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018). Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487318755531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.